QTRX News and Press, Quanterix Corporation From 11/06/23

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023. Third Quarter Financial Highlights Revenue was $31.3 million, an 18% increase f...

2023-11-06 13:45:31 ET Summary Today, we revisit Quanterix Corporation, a life sciences company that develops and markets digital immunoassay platforms. The company has posted much better than expected quarterly numbers over the past two quarters, and third quarter numbers will be...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Quanterix Corporation (QTRX) is expected to report $-0.35 for Q3 2023

2023-11-05 16:35:00 ET More on Quanterix Quanterix: Advancing sNfL Reference Ranges In Pediatric Neurology Canaccord sees solid Q3 earnings for medtech; likes Quanterix, Natera, Guardant Johnson & Johnson inks licensing deal with Quanterix for Alzheimer's testing...

2023-11-01 13:09:36 ET Goldman Sachs published its November “U.S. conviction list.” These are the 25 stocks the brokerage believes are the most differentiated fundamental “buy” ideas across the market. The list, which was introduced on June 1, has two new...

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financial results for the third quarter 2023 after the market closes on Monday, November 6, 2023, and will host a webcast and conference c...

2023-10-29 17:28:12 ET More on Guardant Health, Natera, etc. Natera: Cash Burn Remains A Concern Guardant Health: Peeling Back Economic Layers, Compressed Market Values Appear Justified Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Mar...

New test elevates the performance standard for blood biomarker tests intended for detecting amyloid pathology in individuals with cognitive impairment Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line ...

2023-10-24 06:43:50 ET More on Quanterix Quanterix: Advancing sNfL Reference Ranges In Pediatric Neurology Quanterix Corporation (QTRX) Q2 2023 Earnings Call Transcript Quanterix Corporation 2023 Q2 - Results - Earnings Call Presentation Quanterix upgraded to...